Thirty-five patients were excluded: 3 patients had no tumor cells in the biopsy; 5 patients had less than 50 tumor cells in the biopsy, making it impossible to assure correct results; 19 patients were wild-type EGFR but with insufficient tumor sample after EGFR assessment for BRCA1 expression analysis; 2 patients refused to participate; and 6 patients were withdrawn by their physician due to clinical factors unrelated to the study. Here, EGFR is linked to neoplasm.